PMID- 15155538
OWN - NLM
STAT- MEDLINE
DCOM- 20041227
LR  - 20181113
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 142
IP  - 2
DP  - 2004 May
TI  - Schaffer collateral and perforant path inputs activate different subtypes of NMDA 
      receptors on the same CA1 pyramidal cell.
PG  - 317-22
AB  - The two major inputs to CA1 pyramidal neurons, the perforant pathway (PP) that 
      terminates on distal dendrites and the Schaffer collaterals (SCH) that terminate 
      on proximal dendrites, activate both AMPA and N-methyl-D-aspartate (NMDA) 
      receptors. In an in vitro slice preparation, the pharmacologically isolated NMDA 
      receptor-mediated excitatory postsynaptic currents (EPSCs) (NMDA-EPSCs) of either 
      pathway can be selectively activated onto a single CA1 pyramidal neuron. Analysis 
      of the decay phase of PP and SCH NMDA-EPSCs revealed no significant difference in 
      their time constants, suggesting no apparent different distribution in 
      NR2-subunit composition in the NMDA receptors (NMDAR) activated by the two 
      synaptic inputs. However, application of the NR2B-selective antagonist, 
      ifenprodil, differently affected the NMDA-EPSCs activated by the PP and SCH 
      inputs. The reduction of the PP responses was only 30% compared to 75% for the 
      SCH responses. In addition, for both pathways, the ifenprodil-insensitive 
      component of the NMDA-EPSCs had significantly more rapid decay kinetics than 
      those prior to application of ifenprodil. Our results show a greater NR2B subunit 
      contribution to the NMDA component of the SCH EPSC, compared to the NMDA 
      component of the PP EPSC and that in single CA1 pyramidal neurons NMDA 
      composition is anatomically specific to the afferent input.
FAU - Arrigoni, Elda
AU  - Arrigoni E
AD  - Department of Neurology, Beth Israel Deaconess Medical Center & Harvard Medical 
      School, Boston, MA, U.S.A.
FAU - Greene, Robert W
AU  - Greene RW
LA  - eng
GR  - P50 HL060292/HL/NHLBI NIH HHS/United States
GR  - P50 MH060450/MH/NIMH NIH HHS/United States
GR  - HL 60292/HL/NHLBI NIH HHS/United States
GR  - MH 60450-01A1/MH/NIMH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Quinoxalines)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 118876-58-7 (2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline)
RN  - 6384-92-5 (N-Methylaspartate)
SB  - IM
MH  - Animals
MH  - Excitatory Postsynaptic Potentials/drug effects/*physiology
MH  - N-Methylaspartate/pharmacology
MH  - Perforant Pathway/drug effects/*physiology
MH  - Pyramidal Cells/drug effects/*physiology
MH  - Quinoxalines/pharmacology
MH  - Rats
MH  - Rats, Long-Evans
MH  - Receptors, N-Methyl-D-Aspartate/agonists/antagonists & inhibitors/*physiology
PMC - PMC1574942
EDAT- 2004/05/25 05:00
MHDA- 2004/12/28 09:00
PMCR- 2005/05/01
CRDT- 2004/05/25 05:00
PHST- 2004/05/25 05:00 [pubmed]
PHST- 2004/12/28 09:00 [medline]
PHST- 2004/05/25 05:00 [entrez]
PHST- 2005/05/01 00:00 [pmc-release]
AID - 0705744 [pii]
AID - 10.1038/sj.bjp.0705744 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2004 May;142(2):317-22. doi: 10.1038/sj.bjp.0705744.